DArecca James 4
4 · HAEMONETICS CORP · Filed May 19, 2026
Research Summary
AI-generated summary of this filing
Haemonetics (HAE) CFO DArecca James Receives RSU Award
What Happened
DArecca James, Chief Financial Officer of Haemonetics Corporation (HAE), received an award of 29,312 restricted stock units (RSUs) on May 15, 2026. In connection with vesting of certain previously reported RSUs, 2,505 shares were withheld (disposed) to satisfy tax obligations at an indicated price of $56.29 per share, generating $141,006. The new RSUs are granted under Haemonetics’ 2019 Long-Term Incentive Compensation Plan and are contingent rights to receive one share per RSU when they vest.
Key Details
- Transaction dates: May 15, 2026 (award grant and tax-withholding disposition).
- Award: 29,312 RSUs granted (code A). No immediate cash value reported for the grant on the Form 4.
- Tax withholding: 2,505 shares withheld (code F) at $56.29/share = $141,006 to cover tax liabilities tied to vesting of previously reported RSUs.
- Vesting schedule: RSUs vest in three annual installments — 40% on first anniversary, 40% on second, 20% on third (per footnote). Each RSU equals one share when vested.
- Shares owned after transaction: not specified in this filing.
- Filing timeliness: Report filed May 19, 2026 for transactions dated May 15, 2026 — within the required two business-day reporting window (timely).
- Footnotes: withheld shares were used solely for tax obligations; the reported award includes unvested RSUs previously reported.
Context
RSU grants are compensation and are contingent on future vesting; they are not the same as an open-market purchase (which can be a stronger bullish signal). Withholding shares to satisfy taxes is a routine administrative step and does not necessarily indicate an intent to sell additional shares.
Insider Transaction Report
- Tax Payment
Common Stock
[F1][F2]2026-05-15$56.29/sh−2,505$141,006→ 25,132 total - Award
Common Stock
[F3][F4][F2]2026-05-15+29,312→ 54,444 total
Footnotes (4)
- [F1]Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
- [F2]This number includes unvested RSUs previously reported.
- [F3]The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.
- [F4]Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.